We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

150 hedge funds and large institutions have $1.73B invested in Ventyx Biosciences in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 30

16% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 25

4.44% more ownership

Funds ownership: 85.47%89.91% (+4.4%)

3% more funds holding

Funds holding: 146150 (+4)

4% more capital invested

Capital invested by funds: $1.67B → $1.73B (+$59.7M)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

77% less call options, than puts

Call options by funds: $7.2M | Put options by funds: $31.6M

Holders
150
Holders Change
+4
Holders Change %
+2.74%
% of All Funds
2.36%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.05%
New
29
Increased
70
Reduced
30
Closed
25
Calls
$7.2M
Puts
$31.6M
Net Calls
-$24.4M
Net Calls Change
-$30.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$281M +$32.7M +948,890 +12%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$130M +$43.6M +1,263,761 +47%
BlackRock
3
BlackRock
New York
$106M +$40.6M +1,177,971 +58%
Citadel Advisors
4
Citadel Advisors
Florida
$91.4M -$7.82M -226,891 -8%
Capital International Investors
5
Capital International Investors
California
$89.5M +$12.1M +350,068 +15%
Vanguard Group
6
Vanguard Group
Pennsylvania
$78.2M +$19.9M +577,060 +32%
Lord, Abbett & Co
7
Lord, Abbett & Co
New Jersey
$76M +$34.4M +998,782 +76%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$57.9M +$5.79M +167,891 +11%
Goldman Sachs
9
Goldman Sachs
New York
$51.4M +$7.49M +217,280 +16%
Holocene Advisors
10
Holocene Advisors
New York
$50.4M +$17.3M +500,571 +48%
Wellington Management Group
11
Wellington Management Group
Massachusetts
$44.3M +$16.5M +479,127 +55%
State Street
12
State Street
Massachusetts
$34.1M +$15.2M +440,271 +73%
Loomis, Sayles & Company
13
Loomis, Sayles & Company
Massachusetts
$32.7M +$34.4M +998,237 New
DCM
14
Driehaus Capital Management
Illinois
$31.6M +$933K +27,075 +3%
RG
15
Redmile Group
California
$30.8M +$4.3M +124,719 +15%
T. Rowe Price Investment Management
16
T. Rowe Price Investment Management
Maryland
$29.8M +$11.9M +345,086 +61%
BC
17
Boxer Capital
California
$27.9M
TCM
18
TCG Crossover Management
California
$26.8M
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$26.2M -$9.32M -270,400 -25%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$25.4M +$8.22M +238,578 +44%
PAMS
21
Pictet Asset Management (Switzerland)
Switzerland
$24.8M +$411K +11,931 +2%
QUSVM
22
Qiming U.S. Ventures Management
Washington
$24.5M
APM
23
Avidity Partners Management
Texas
$22.7M -$42.2M -1,225,300 -64%
DM
24
Deerfield Management
New York
$20.2M
O
25
OrbiMed
New York
$17.7M -$1.52M -44,016 -8%

VTYX Hedge Fund Activity: Q2 2023 in Review

150 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q2 2023, worth a combined $1.73B — up 3.6% from $1.67B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new VTYX positions and 25 closed out — a net gain of 4 holders — while 70 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $43.6M. The largest seller was venBio Partners, cutting an estimated $64.6M.

  • 150 institutional investors held Ventyx Biosciences (VTYX) as of Q2 2023, up from 146 in Q1 2023.
  • Funds reported $1.73B of Ventyx Biosciences stock for Q2 2023, up 3.6% quarter-over-quarter.
  • 29 funds opened new Ventyx Biosciences positions in Q2 2023 and 25 closed out, a net change of +4 holders.
  • The largest Ventyx Biosciences buyer in Q2 2023 was T. Rowe Price Associates, an estimated $43.6M added.
  • The largest Ventyx Biosciences seller in Q2 2023 was venBio Partners, an estimated $64.6M sold.

Based on aggregated 13F filings for Q2 2023.